Featured Publications
Patient-level and external factors in the use of drug-coated balloons and drug-eluting stents in femoropopliteal endovascular interventions
Castro-Dominguez Y, Smolderen KG, Pichert M, Alabi O, Romain G, Huang J, Lee M, Ahmed Z, Peri-Okonny PA, Arham A, Brice A, Chaar CO, Stacy MR, Mena-Hurtado C. Patient-level and external factors in the use of drug-coated balloons and drug-eluting stents in femoropopliteal endovascular interventions. Journal Of Vascular Surgery 2022, 76: 1675-1680. PMID: 35868423, DOI: 10.1016/j.jvs.2022.06.093.Peer-Reviewed Original ResearchConceptsDrug-coated balloonsDrug-eluting stentsBare metal stentsDES useFemoropopliteal endovascular interventionEndovascular interventionMedian odds ratioFemoropopliteal diseaseLesion characteristicsPrimary treatmentChronic kidney disease stage 4Adjusted median odds ratioVascular Quality Initiative registryAppropriate use guidelinesPrior anticoagulant usePatient-level factorsPoor functional statusTrans-Atlantic InterPlain balloon angioplastyPatient-level characteristicsFavorable patency ratesHierarchical logistic regression modelsLogistic regression modelsMeta-analysis publicationsRutherford classificationUse of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease
Castro-Dominguez Y, Smolderen K, Romain G, Turner J, Mena-Hurtado C. Use of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease. Vascular Medicine 2023, 28: 150-152. PMID: 36710497, DOI: 10.1177/1358863x221148521.Peer-Reviewed Original Research
2023
Drug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease
Hanna J, Smolderen K, Castro‐Dominguez Y, Romain G, Lee M, Turner J, Mena‐Hurtado C. Drug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease. Journal Of The American Heart Association 2023, 12: e028622. PMID: 36974774, PMCID: PMC10122876, DOI: 10.1161/jaha.122.028622.Peer-Reviewed Original ResearchConceptsEarly-stage chronic kidney diseaseChronic kidney diseaseBare metal stentsDrug-eluting stentsDrug-coated balloonsMortality riskAmputation riskKidney diseaseSevere chronic kidney diseaseMajor amputation riskPlain balloon angioplastyDrug-Coated BalloonAmputation outcomesCKD statusAmputation rateCause mortalityBackground PatientsAdjusted analysisBalloon angioplastyFemoropopliteal interventionsDES useBMS useRegistry dataDisease trialsPatients
2021
Trends in drug-coated device use for peripheral artery disease: Insights from the Vascular Quality Initiative (VQI)
Pichert MD, Smolderen KG, Castro-Dominguez Y, Jelani QU, Nagpal S, Provance JB, Huang J, Malik AO, Secemsky EA, Derbas LA, Mena-Hurtado CI. Trends in drug-coated device use for peripheral artery disease: Insights from the Vascular Quality Initiative (VQI). Vascular Medicine 2021, 27: 73-74. PMID: 34610776, DOI: 10.1177/1358863x211043567.Peer-Reviewed Original Research
2020
Intravascular Lithotripsy for Treatment of Calcified Lesions During Carotid Artery Stenting
Giannopoulos S, Speziale F, Vadalà G, Soukas P, Kuhn BA, Stoltz CL, Foteh MI, Mena-Hurtado C, Armstrong EJ. Intravascular Lithotripsy for Treatment of Calcified Lesions During Carotid Artery Stenting. Journal Of Endovascular Therapy 2020, 28: 93-99. PMID: 32869718, DOI: 10.1177/1526602820954244.Peer-Reviewed Original ResearchConceptsCarotid artery lesionsIntravascular lithotripsyArtery lesionsCarotid duplex ultrasound examinationAortic arch manipulationDual antiplatelet therapyCarotid artery stentingEmbolic protection devicesDuplex ultrasound examinationCarotid artery stenosisLong-term safetyArch manipulationBaseline stenosisAntiplatelet therapyAsymptomatic patientsSignificant restenosisIschemic strokeISR lesionsRisk patientsStent restenosesTransfemoral accessAdverse eventsArtery stentingArtery stenosisSymptomatic bradycardiaSafety and efficacy of paclitaxel drug-coated balloon in femoropopliteal in-stent restenosis
Anantha-Narayanan M, Love K, Nagpal S, Sheikh AB, Regan CJ, Mena-Hurtado C. Safety and efficacy of paclitaxel drug-coated balloon in femoropopliteal in-stent restenosis. Expert Review Of Medical Devices 2020, 17: 533-539. PMID: 32525406, DOI: 10.1080/17434440.2020.1770593.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, BalloonCoronary RestenosisFemoral ArteryHumansPaclitaxelPopliteal ArteryRandomized Controlled Trials as TopicStentsConceptsDrug-coated balloonsPlain old balloon angioplastyPeripheral arterial diseaseFP-ISRFP diseaseStent restenosisEfficacy of DCBUse of DCBPaclitaxel drug-coated balloonFirst-line therapyRecurrence of symptomsSelf-expanding nitinol stentsHigher patency rateLong-term safetyLesion revascularizationEndovascular therapyISR rateRandomized studyArterial diseaseBalloon angioplastyFemoropopliteal segmentPatency ratesCommon siteTerm safetyNitinol stents
2019
Drug‐coated balloon versus plain old balloon angioplasty in femoropopliteal disease: An updated meta‐analysis of randomized controlled trials
Anantha‐Narayanan M, Shah SM, Jelani Q, Garcia S, Ionescu C, Regan C, Mena‐Hurtado C. Drug‐coated balloon versus plain old balloon angioplasty in femoropopliteal disease: An updated meta‐analysis of randomized controlled trials. Catheterization And Cardiovascular Interventions 2019, 94: 139-148. PMID: 30838719, DOI: 10.1002/ccd.28176.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmputation, SurgicalAngioplasty, BalloonCardiovascular AgentsCoated Materials, BiocompatibleEquipment DesignFemaleFemoral ArteryHumansLimb SalvageMalePeripheral Arterial DiseasePopliteal ArteryRandomized Controlled Trials as TopicRisk FactorsTreatment OutcomeVascular Access DevicesVascular PatencyConceptsTarget vessel revascularizationPeripheral arterial diseaseFemoropopliteal diseaseBalloon angioplastyRate of TVRDrug-coated balloon angioplastyPlain old balloon angioplastyAvailable RCT dataDevice-related mortalityImproved vessel patencyPrimary safety endpointMainstay of therapyCochrane's Q statisticLate lumen lossDrug-coated balloonsRandom-effects modelQ statisticMajor amputationSafety endpointVessel revascularizationDCB groupPopliteal arteryArterial diseaseUse of DCBLumen loss
2017
Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease
Krishnan P, Faries P, Niazi K, Jain A, Sachar R, Bachinsky WB, Cardenas J, Werner M, Brodmann M, Mustapha JA, Mena-Hurtado C, Jaff MR, Holden AH, Lyden SP, Mewissen M, Katzen B, Nanjundappa A, Khuddus M, Ricci J, Fry D, Shishehbor M, Bosarge C, Kovach R, Goodwin M, Raja M, Mayeda G, Sandhu J, Rosales O, Crowder W, Paolini D, Henretta J, Desai P, Farhat N, Kang E, Ansel G, Ghani M, Miller W, Pollock C, Korngold E, Angle J, Schultz G, Gensler T, Lopez L, Park J, Al-Khoury G, Joels C, Metzger C. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease. Circulation 2017, 136: 1102-1113. PMID: 28729250, PMCID: PMC5598919, DOI: 10.1161/circulationaha.117.028893.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, BalloonCardiovascular AgentsCoated Materials, BiocompatibleFemaleFemoral ArteryHalf-LifeHumansKaplan-Meier EstimateMaleMiddle AgedPaclitaxelPeripheral Arterial DiseaseProspective StudiesSeverity of Illness IndexSingle-Blind MethodTime FactorsTreatment OutcomeVascular PatencyConceptsDrug-coated balloonsPrimary safety end pointSafety end pointTarget lesion revascularizationLesion revascularizationPrimary patencyEnd pointFemoropopliteal diseaseClinical outcomesPivotal studiesDifferent drug-coated balloonsPrimary effectiveness end pointStellarex drug-coated balloonTarget limb major amputationEffectiveness end pointAnkle-brachial indexProcedure-related deathsFemoropopliteal artery diseasePrimary patency rateDrug-Coated BalloonKaplan-Meier estimatesPaclitaxel plasma concentrationsQuality of lifeDCB cohortMajor amputation
2015
Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease
Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, Brodmann M, Pilger E, Zeller T, Krishnan P, Gammon R, Müller-Hülsbeck S, Nehler MR, Benenati JF, Scheinert D. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. New England Journal Of Medicine 2015, 373: 145-153. PMID: 26106946, DOI: 10.1056/nejmoa1406235.Peer-Reviewed Original ResearchConceptsDrug-coated balloonsPaclitaxel-coated balloonPeripheral artery diseasePercutaneous transluminal angioplastyPrimary patencyArtery diseaseTransluminal angioplastyStandard angioplastyStandard balloonSymptomatic femoropopliteal peripheral artery diseaseFemoropopliteal peripheral artery diseasePrimary efficacy end pointPrimary safety end pointEnd pointSignificant between-group differencesComposite of freedomPrimary safety eventsSymptomatic intermittent claudicationEfficacy end pointSafety end pointFemoropopliteal artery diseaseProportion of patientsSignificant atherosclerotic lesionsBetween-group differencesRate of deathLocal delivery of paclitaxel in the treatment of peripheral arterial disease
Ng VG, Mena C, Pietras C, Lansky AJ. Local delivery of paclitaxel in the treatment of peripheral arterial disease. European Journal Of Clinical Investigation 2015, 45: 333-345. PMID: 25615282, DOI: 10.1111/eci.12407.Peer-Reviewed Original ResearchConceptsPeripheral artery diseaseEndovascular revascularizationArtery diseaseLocal deliveryClinical studiesLocal drug deliveryPeripheral arterial diseasePeripheral vascular diseasePrimary patency rateSystemic adverse effectsUse of paclitaxelLong-term efficacyDrug-Eluting BalloonDrug-eluting stentsTerms of efficacyBrief exposure periodArterial diseaseBalloon angioplastyPatency ratesVascular diseaseBalloon catheterCoated balloonMEDLINE searchStent failureActive drug
2014
Randomized Controlled Study of Excimer Laser Atherectomy for Treatment of Femoropopliteal In-Stent Restenosis Initial Results From the EXCITE ISR Trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis)
Dippel EJ, Makam P, Kovach R, George JC, Patlola R, Metzger DC, Mena-Hurtado C, Beasley R, Soukas P, Colon-Hernandez PJ, Stark MA, Walker C, Investigators E. Randomized Controlled Study of Excimer Laser Atherectomy for Treatment of Femoropopliteal In-Stent Restenosis Initial Results From the EXCITE ISR Trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis). JACC Cardiovascular Interventions 2014, 8: 92-101. PMID: 25499305, DOI: 10.1016/j.jcin.2014.09.009.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlloysAmputation, SurgicalAngioplasty, BalloonAtherectomyChronic DiseaseCombined Modality TherapyConstriction, PathologicFemaleFemoral ArteryHumansLaser TherapyLasers, ExcimerLimb SalvageMaleMiddle AgedPeripheral Arterial DiseasePopliteal ArteryProspective StudiesProsthesis DesignRecurrenceStentsTime FactorsTreatment OutcomeUnited StatesVascular PatencyConceptsPercutaneous transluminal angioplastyTarget lesion revascularizationExcimer laser atherectomyLaser atherectomyAdjunctive percutaneous transluminal angioplastyMajor adverse event rateChronic peripheral artery diseaseLesion lengthLifestyle-limiting claudicationPrimary safety endpointRutherford class 1Target lesion lengthPrimary efficacy endpointMajor adverse eventsPeripheral artery diseaseAdverse event ratesCritical limb ischemiaFemoropopliteal ISRLesion revascularizationEfficacy endpointSafety endpointAdverse eventsLimb ischemiaTransluminal angioplastyArtery diseaseRole of laser atherectomy for the management of in-stent restenosis in the peripheral arteries.
Jayasuriya S, Ward C, Mena-Hurtado C. Role of laser atherectomy for the management of in-stent restenosis in the peripheral arteries. The Journal Of Cardiovascular Surgery 2014, 55: 339-45. PMID: 24755702.Peer-Reviewed Original ResearchConceptsStent restenosisPeripheral arteriesLaser atherectomyPeripheral vascular diseasePrevalence of PADExcimer laser atherectomySurgical revascularizationClinical improvementEndovascular treatmentEndovascular techniquesPeripheral lesionsVascular diseaseChronic diseasesLower extremitiesEndovascular specialistsPopulation agesRestenosisRevascularizationAtherectomyArteryTreatmentDiseaseLesionsPrevalenceExtremities